Mutagenic and clastogenic activity of gastric juice in human gastric diseases.
To investigate whether subjects with low-acid states are exposed to increased genetic risk with respect to controls, we evaluated mutagenicity and presence of clastogenic factors (CF) in the gastric juice of chronic atrophic gastritis and omeprazole-treated patients. Mutagenic gastric juice was found in 8/15 (53%) chronic atrophic gastritis patients, 8/11 (73%) omeprazole-treated patients, and 2/13 (15%) healthy control subjects. The mean mutagenicity ratio of omeprazole-treated patients (1.52+/-0.48/0.1 ml gastric juice) was significantly higher than those of either controls (1.07+/-0.15; P<0.01) or chronic atrophic gastritis patients (1.16+/-0.21; P<0.05). Only chronic atrophic gastritis patients showed an increased clastogenic index with respect to healthy controls (2.67+/-2.13 versus 0.38+/-0.51; P<0.001). These findings expand our knowledge of gastric disease risk factors, and indicate that there may well be a risk of mucosal DNA damage arising from the presence of mutagenic and CF in the gastric juice.
Hrelia
P
P
Dipartimento di Farmacologia, Universita' degli Studi di Bologna, Via Irnerio 48, 40126, Bologna, Italy. phrelia@biocfarm.unibo.it
Fimognari
C
C
Maffei
F
F
Brandi
G
G
Biasco
G
G
Cantelli-Forti
G
G
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D005750:Gastric Juice / Q000737:chemistry* / Q000378:metabolism; D005757:Gastritis, Atrophic / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009152:Mutagenicity Tests; D009153:Mutagens; D009853:Omeprazole / Q000627:therapeutic use; D012907:Smoking; D013272:Stomach Diseases / Q000235:genetics / Q000503:physiopathology*
D000897:Anti-Ulcer Agents; D009153:Mutagens; D009853:Omeprazole